Notice ID: b69837c6d9fa4e25aead542e58e922cfSolicitation
Using Transgenic Mouse to Generate Human Antibodies
Archived on June 15, 2022. Original response deadline: . Full description on SAM.gov.
Overview
- Response deadline
- 5:00 PM UTC−04:00
- Posted
- May 17, 2022
- Notice type
- Solicitation
- NAICS
- 541714: Research and Development in Biotechnology (except Nanobiotechnology)
- Agency
- Department of Health and Human ServicesCENTERS FOR DISEASE CONTROL AND PREVENTION
Notice details
- Office
- CDC OFFICE OF ACQUISITION SERVICES
- Place of performance
- Atlanta, GA, 30329
- Last updated
- Dec 4, 2025
Identifiers
- Solicitation number
- 75D301-22-Q-74781
- Notice ID
- b69837c6d9fa4e25aead542e58e922cf
Description
CDC seeks to test a transgenic mouse model that is engineered with human immunoglobulin gene segments to produce humanized antibodies, with the goal of determining if the antibodies generated from that mouse model can better recapitulate the antibody repertoire from humans. Overall objective is to provide the Influenza Division with transgenic mice that express human antibody repertoire, which would be useful for assessing the efficacy of CVVs and developing antibodies.
Award Overview
No prior contract identified
No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.
Contacts
Documents
No documents available.
Lifecycle
Solicitation:
75D301-22-Q-74781- Solicitation
Award typically follows within 30–90 days after the response deadline. (estimate)
- SolicitationCurrentMay 17, 2022
Using Transgenic Mouse to Generate Human Antibodies
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
Additional Details
Solicitation Number
75D301-22-Q-74781
Archive Date
Jun 15, 2022
Office Address
ATLANTA, GA, 30333